JP7837338B2 - 骨髄異形成症候群の処置における使用のためのタスキニモドまたはその薬学的に許容される塩 - Google Patents

骨髄異形成症候群の処置における使用のためのタスキニモドまたはその薬学的に許容される塩

Info

Publication number
JP7837338B2
JP7837338B2 JP2023541564A JP2023541564A JP7837338B2 JP 7837338 B2 JP7837338 B2 JP 7837338B2 JP 2023541564 A JP2023541564 A JP 2023541564A JP 2023541564 A JP2023541564 A JP 2023541564A JP 7837338 B2 JP7837338 B2 JP 7837338B2
Authority
JP
Japan
Prior art keywords
mds
pharmaceutical composition
composition according
tascinimod
risk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023541564A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024503372A5 (https=
JP2024503372A (ja
Inventor
ウォバス，マーニャ
ゾッケル，カチャ
ボーンホイザー，マルティン
Original Assignee
アクティブ バイオテック エイビー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アクティブ バイオテック エイビー filed Critical アクティブ バイオテック エイビー
Publication of JP2024503372A publication Critical patent/JP2024503372A/ja
Publication of JP2024503372A5 publication Critical patent/JP2024503372A5/ja
Application granted granted Critical
Publication of JP7837338B2 publication Critical patent/JP7837338B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2023541564A 2021-01-18 2022-01-17 骨髄異形成症候群の処置における使用のためのタスキニモドまたはその薬学的に許容される塩 Active JP7837338B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP21152018.4 2021-01-18
EP21152018 2021-01-18
EP21201509.3 2021-10-07
EP21201509 2021-10-07
EP21205665 2021-10-29
EP21205665.9 2021-10-29
PCT/EP2022/050891 WO2022152902A1 (en) 2021-01-18 2022-01-17 Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome

Publications (3)

Publication Number Publication Date
JP2024503372A JP2024503372A (ja) 2024-01-25
JP2024503372A5 JP2024503372A5 (https=) 2025-01-16
JP7837338B2 true JP7837338B2 (ja) 2026-03-30

Family

ID=80034981

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023541564A Active JP7837338B2 (ja) 2021-01-18 2022-01-17 骨髄異形成症候群の処置における使用のためのタスキニモドまたはその薬学的に許容される塩

Country Status (12)

Country Link
US (1) US20240091215A1 (https=)
EP (1) EP4277628B1 (https=)
JP (1) JP7837338B2 (https=)
KR (1) KR20230133317A (https=)
AU (1) AU2022208424A1 (https=)
CA (1) CA3204120A1 (https=)
ES (1) ES3057099T3 (https=)
IL (1) IL304232A (https=)
MX (1) MX2023008016A (https=)
PL (1) PL4277628T3 (https=)
WO (1) WO2022152902A1 (https=)
ZA (1) ZA202307855B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL4346773T3 (pl) 2021-05-25 2025-11-03 Active Biotech Ab Duża liczba cząstek taskwinimodu i ich zastosowanie
WO2024137713A1 (en) * 2022-12-20 2024-06-27 Constellation Pharmaceuticals, Inc. Methods for treating lower risk myelodysplastic syndrome

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006507271A (ja) 2002-10-15 2006-03-02 セルジーン・コーポレーション 骨髄異形成症候群を治療および管理するための免疫調節化合物の使用方法およびそれを含む組成物
JP2016523930A (ja) 2013-07-05 2016-08-12 エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド 骨髄異形成症候群（ｍｄｓ）を治療するための可溶性ｃｄ３３
JP2017506659A (ja) 2014-02-28 2017-03-09 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ 骨髄異形成症候群の治療のためのｊａｋ１阻害剤
JP2017534652A (ja) 2014-11-19 2017-11-24 アクティブ バイオテック エイビー 白血病の治療に使用するためのキノリンカルボキサミド
JP2019127473A (ja) 2018-01-26 2019-08-01 学校法人同志社 多発性硬化症の治療及び／又は予防のための薬剤
JP2020536869A (ja) 2017-10-06 2020-12-17 テサロ， インコーポレイテッド 併用療法およびその使用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9801474D0 (sv) 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
SE9802549D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
SE0002320D0 (sv) 1999-10-25 2000-06-21 Active Biotech Ab Malignant tumors
SE0201778D0 (sv) 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
SG186430A1 (en) 2010-07-09 2013-01-30 Active Biotech Ab Method for manufacturing of quinoline-3-carboxamides
EP2537517A1 (en) 2011-06-22 2012-12-26 Active Biotech AB Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
JP6647287B2 (ja) * 2014-09-23 2020-02-14 アクティブ バイオテック エイビー 多発性骨髄腫の治療に使用するためのキノリンカルボキサミド
EP3067062A1 (en) 2015-03-13 2016-09-14 Ipsen Pharma S.A.S. Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006507271A (ja) 2002-10-15 2006-03-02 セルジーン・コーポレーション 骨髄異形成症候群を治療および管理するための免疫調節化合物の使用方法およびそれを含む組成物
JP2016523930A (ja) 2013-07-05 2016-08-12 エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド 骨髄異形成症候群（ｍｄｓ）を治療するための可溶性ｃｄ３３
JP2017506659A (ja) 2014-02-28 2017-03-09 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ 骨髄異形成症候群の治療のためのｊａｋ１阻害剤
JP2017534652A (ja) 2014-11-19 2017-11-24 アクティブ バイオテック エイビー 白血病の治療に使用するためのキノリンカルボキサミド
JP2020536869A (ja) 2017-10-06 2020-12-17 テサロ， インコーポレイテッド 併用療法およびその使用
JP2019127473A (ja) 2018-01-26 2019-08-01 学校法人同志社 多発性硬化症の治療及び／又は予防のための薬剤

Also Published As

Publication number Publication date
CA3204120A1 (en) 2022-07-21
EP4277628C0 (en) 2025-09-24
WO2022152902A1 (en) 2022-07-21
IL304232A (en) 2023-09-01
EP4277628A1 (en) 2023-11-22
AU2022208424A1 (en) 2023-08-24
KR20230133317A (ko) 2023-09-19
ZA202307855B (en) 2025-12-17
PL4277628T3 (pl) 2026-02-09
JP2024503372A (ja) 2024-01-25
ES3057099T3 (en) 2026-02-26
EP4277628B1 (en) 2025-09-24
AU2022208424A9 (en) 2024-05-09
US20240091215A1 (en) 2024-03-21
MX2023008016A (es) 2023-07-13

Similar Documents

Publication Publication Date Title
Yang et al. The mechanisms of pathological extramedullary hematopoiesis in diseases
Rogers et al. Disease-modifying bioactivity of intravenous cardiosphere-derived cells and exosomes in mdx mice
JP6992809B2 (ja) 免疫疾患の治療のための高効能幹細胞の選別方法
Xagorari et al. Protective effect of mesenchymal stem cell-conditioned medium on hepatic cell apoptosis after acute liver injury
Peng et al. Macrophages: subtypes, distribution, polarization, immunomodulatory functions, and therapeutics
CN109641002B (zh) 血液癌症的组合治疗
JP7837338B2 (ja) 骨髄異形成症候群の処置における使用のためのタスキニモドまたはその薬学的に許容される塩
EP4185292B1 (en) S100 proteins as novel therapeutic targets in myeloproliferative neoplasms
Meyer et al. Silencing the CSF-1 axis using nanoparticle encapsulated siRNA mitigates viral and autoimmune myocarditis
Qiu et al. Myeloid-derived suppressor cells alleviate renal fibrosis progression via regulation of CCL5-CCR5 axis
US20100004244A1 (en) Use of cb2 receptor agonists for promoting neurogenesis
Kim et al. Expression and functional roles of the chemokine receptor CXCR7 in acute myeloid leukemia cells
JP2023504424A (ja) 代謝は内皮から造血への移行中の決定的系統指定を誘導する
US20240165090A1 (en) Methods and compositions for improving bone marrow hematopoietic functions
JP2022531269A (ja) 異常ヘモグロビン症の治療の有効性を予測するための方法
US9199028B2 (en) Use of entrained neutrophils to treat metastatic and micrometastatic disease in at risk patients
CN110551688B (zh) 一种诱导体细胞重编程为造血干/祖细胞且促进造血干/祖细胞体外扩增的组合物及其应用
CN116887844A (zh) 用于治疗骨髓增生异常综合征的他喹莫德或其药学上可接受的盐
Sun et al. NANOG has a role in mesenchymal stem cells' immunomodulatory effect
CN115998744A (zh) 一种新戊酰胺化合物在制备治疗缺血性脑卒中药物、制备ido1酶抑制剂中的应用
Xiong et al. The experimental research of pregnancy immune tolerance induced by FTY720 via blocking S1P signal transduction pathway
Li et al. Interleukin 8/KC enhances G-CSF induced hematopoietic stem/progenitor cell mobilization in Fancg deficient mice
JP2020011915A (ja) エイコサノイド産生促進剤
Humphrey Pro-tumor myeloid cells in the leukemia microenvironment: T-ALL
Gao et al. FHL2 deficiency aggravates Candida albicans infection through decreased myelopoiesis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250107

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250107

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251017

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251027

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260227

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260317

R150 Certificate of patent or registration of utility model

Ref document number: 7837338

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150